[go: up one dir, main page]

DE69730358D1 - Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD - Google Patents

Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD

Info

Publication number
DE69730358D1
DE69730358D1 DE69730358T DE69730358T DE69730358D1 DE 69730358 D1 DE69730358 D1 DE 69730358D1 DE 69730358 T DE69730358 T DE 69730358T DE 69730358 T DE69730358 T DE 69730358T DE 69730358 D1 DE69730358 D1 DE 69730358D1
Authority
DE
Germany
Prior art keywords
gvhd
prophylaxis
therapy
fas antagonist
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730358T
Other languages
English (en)
Other versions
DE69730358T2 (de
Inventor
Shigekazu Nagata
Takehiro Yatomi
Takashi Suda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Bioscience Institute
Mochida Pharmaceutical Co Ltd
Original Assignee
Osaka Bioscience Institute
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Bioscience Institute, Mochida Pharmaceutical Co Ltd filed Critical Osaka Bioscience Institute
Publication of DE69730358D1 publication Critical patent/DE69730358D1/de
Application granted granted Critical
Publication of DE69730358T2 publication Critical patent/DE69730358T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69730358T 1996-10-31 1997-10-31 Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD Expired - Lifetime DE69730358T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP29045996 1996-10-31
JP29045996 1996-10-31
JP35171896 1996-12-27
JP35171896 1996-12-27
JP26252197 1997-09-26
JP26252197 1997-09-26
PCT/JP1997/003978 WO1998018487A1 (en) 1996-10-31 1997-10-31 Prophylactic/remedial agent

Publications (2)

Publication Number Publication Date
DE69730358D1 true DE69730358D1 (de) 2004-09-23
DE69730358T2 DE69730358T2 (de) 2004-12-30

Family

ID=27335136

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730358T Expired - Lifetime DE69730358T2 (de) 1996-10-31 1997-10-31 Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD

Country Status (8)

Country Link
US (1) US7128905B2 (de)
EP (2) EP1449539A2 (de)
JP (1) JP4339405B2 (de)
AT (1) ATE273713T1 (de)
AU (1) AU4726797A (de)
CA (1) CA2270423C (de)
DE (1) DE69730358T2 (de)
WO (1) WO1998018487A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562342B1 (en) 1998-02-06 2003-05-13 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for inflammatory intestinal disease
DE69932434D1 (de) * 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
WO2004022545A1 (ja) * 2002-09-06 2004-03-18 Mitsubishi Pharma Corporation 移植臓器保護剤
EP1447093A1 (de) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen
PT1606318E (pt) 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
EP1839675A1 (de) * 2004-09-28 2007-10-03 Japan Science and Technology Agency Neues verfahren zum schutz vor ischämischer kardiopathie
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2010006772A2 (en) * 2008-07-14 2010-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CA2735587A1 (en) * 2008-08-28 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
WO2014013039A1 (en) * 2012-07-18 2014-01-23 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
AU2021372463A1 (en) 2020-10-28 2023-06-22 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5663070A (en) * 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
EP0739350B1 (de) 1994-01-07 2008-02-27 Mochida Pharmaceutical Co., Ltd. Fas-antigenbindender ligand
JPH07289266A (ja) * 1994-04-21 1995-11-07 Mochida Pharmaceut Co Ltd ヒトＦａｓ抗原バリアント及びそれをコードする新規ＤＮＡ
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
JP3055006B2 (ja) * 1994-09-27 2000-06-19 参天製薬株式会社 リウマチ治療剤
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
WO1997012632A1 (en) * 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression

Also Published As

Publication number Publication date
ATE273713T1 (de) 2004-09-15
US20030109416A1 (en) 2003-06-12
CA2270423A1 (en) 1998-05-07
WO1998018487A1 (en) 1998-05-07
EP0992243B1 (de) 2004-08-18
DE69730358T2 (de) 2004-12-30
CA2270423C (en) 2009-09-15
AU4726797A (en) 1998-05-22
JP4339405B2 (ja) 2009-10-07
EP0992243A4 (de) 2000-04-12
EP0992243A1 (de) 2000-04-12
EP1449539A2 (de) 2004-08-25
US7128905B2 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
NZ335981A (en) Ketobenzamides as calpain inhibitors
ATE235906T1 (de) Substituierte phenylpyrimidine derivate, für die behandlung oder prevention von zns-erkrankungen
DE69730358D1 (de) Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
DE69510696D1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen
CA2241981A1 (en) Method of inhibiting photoaging of skin
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
PT880350E (pt) Tratamento de esclerose multipla
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE3587741D1 (de) Behandlung von Hautkrankheiten.
AU4089889A (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
MX9703693A (es) Tratamiento profilactico de dermatitis alergica por contacto.
DE3584560D1 (de) Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
ATE78171T1 (de) Gangliosidgemisch zur verwendung als therapeutisches hilfsmittel zur schmerzunterdrueckung bei peripheren neuropathien.
ZA898605B (en) Compositions for topical treatment of skin diseases
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
FR2524486B1 (fr) Souches de champignon pour le traitement des maladies fongiques des plantes et utilisation de ces souches
BE884756A (fr) Composition dermatologique pour le traitement des maladies de la peau, accompagnees d'une proliferation cellulaire, telles que le psoriasis
NO984245L (no) Nasal administrasjon av midler for behandling av emesis med forsinket begynnelse
GB2163051A (en) Medicinal composition for the treatment or prevention of acne by topical application
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
NO962221L (no) Anvendelse av dimeticon for behandling av konstipasjon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition